Although the CYP2C19 genotype was significantly associated with the prognosis of patients with CHD [39], findings from the PLATO study [40] indicated that although CYP2C19 loss‐allele carriers had significantly higher rates of primary cardiovascular endpoint events at 30 days compared with noncarriers, this difference was not statistically significant at 12 months of follow‐up in ACS patients treated with clopidogrel. This evidence concerns the gene CYP2C19 and coronary artery disorder.